List of PGRN-RIKEN Projects


Full Publication List




Kathleen M. Giacomini, PhD
Michiaki Kubo, MD PhD
Mark J. Ratain, MD

Project Director

Sook Wah Yee, PhD

PGRN-Hub Project Director

Lawrence Lin, PhD

Steering Committee

Kathleen M. Giacomini, PhD
Mark J. Ratain, MD
Yoichiro Kamatani, MD, PhD
Michiaki Kubo, MD PhD
Yukihide Momozawa, DVM, PhD
Richard M. Weinshilboum, MD
Sook Wah Yee, PhD

Scientific Advisory Board

Nancy J. Cox, PhD
Dan M. Roden, MD
Tatsuhiko Tsunoda, MD, PhD
Rachel F. Tyndale, PhD

NIH Liaison

Kelly Filipski, PhD
Rochelle M. Long, PhD
Full Investigator List


The GAP-J (currently known as PGRN-RIKEN) was formally launched in the Spring of 2008. PGRN-RIKEN (previously known as GAP-J) was the brainchild of Dr. Yusuke Nakamura, Former Director of the RIKEN, and Drs. Mark J. Ratain and Kathleen M. Giacomini, Principal Investigators in the PGRN. After a series of discussions on the need to accelerate discoveries in pharmacogenomics, Drs. Nakamura, Ratain and Giacomini decided to try to utilize the complementary resources and expertise of the PGRN and the RIKEN (see GAP-J Letter of Intent). The PGRN has been successful assembling an abundance of DNA samples from well-phenotyped patients for specific drugs and drug combinations. The RIKEN focuses on high-throughput services for SNP analysis and has developed extraordinarily powerful genomewide technologies to identify genes that determine susceptibility to various disease and response to treatment. Together, the PGRN-RIKEN capitalizes on these strength to advance discoveries in personalized medicines and benefit global populations. Since 2012, Drs. Giacomini, Kubo and Ratain have co-lead the PGRN-RIKEN collaborative studies. This study was supported by the NIH Pharmacogenomics Research Network (PGRN)-RIKEN Global Alliance (U19 GM061390, 2010 – 2015).